March 2016 - Biowebspin | Biowebspin
Logo Biowebspin

Archives March 2016 - Biowebspin

Didier Hoch is speaking about the Biovision Forum, 13 – 14 April 2016 at Lyon, France

Didier Hoch is speaking about the Biovision Forum, 13 – 14 April 2016 at Lyon, France

Didier Hoch is speaking about the Biovision Forum, 13 - 14 April 2016 at Lyon, France. About Didier Hoch: -Chairman at Biovision -Director of Big Booster -Board member of DBV Technologies, Effimune, Genticel   »

Mohammed Charki is sharing his experience in building Academic-Industry partnerships

Mohammed Charki is sharing his experience in building Academic-Industry partnerships

Mr Charki is sharing his experience in building Academic-Industry partnerships. About Mohammed Charki: -Board member at Aenitis Technologies -Board member at BBP SAS -Board member at Algama SAS -2010-2015 Open Innovation Strategy, Scouting & Partnerships at Sanofi »

Who is the academic entrepreneur? The role of graduate students in the development of university spinoffs

Who is the academic entrepreneur? The role of graduate students in the development of university spinoffs

  Biowebspin, March 24th, 2016 Who is the academic entrepreneur? The role of graduate students in the development of university spinoffs by Christopher S. Hayter, Roman Lubynsky, Spiro Maroulis in Journal of Technology Transfer, 2016 Academic entrepreneurship, the establishment of new companies based on technologies derived from university research, is a well-recognized driver of regional and nati... »

Participation and Contribution in Crowdsourced Surveys

Participation and Contribution in Crowdsourced Surveys

  Biowebspin, March 21th, 2016 Participation and Contribution in Crowdsourced Surveys by Robert Swain, Alex Berger, Josh Bongard, Paul Hines in Swiss medical weekly, 2015 This paper identifies trends within and relationships between the amount of participation and the quality of contributions in three crowdsourced surveys. Participants were asked to perform a collective problem solving task that l... »

Kristof-van-Emelen

Kristof van Emelen is speaking about open innovation at Janssen

Kristof van Emelen is  speaking about open innovation at Janssen. About Kristof van Emelen: -Director Emerging Sciences and Innovation at Janssen Pharmaceutical -Contributed to the discovery of R306465, a novel inhibitor of class I histone deacetylases with broad-spectrum anti-tumoral activity -2007/2011: Director of Medicinal Chemistry at Tibotec -Ph.D. degree in organic chemistry See Biowebspin'... »

Kamal-Azzaoui

Kamal Azzaoui, Novartis, about “Scientific competency questions as the basis for semantically enriched open pharmacological space development”

Kamal Azzaoui is speaking about the main message of his publication ‘Scientific competency questions as the basis for semantically enriched open pharmacological space development’ (see also the abstract below). He explains why collaboration between academia and industry is important and finally gives advices.   Scientific competency questions as the basis for semantically enriched open pharma... »

David Andrews, Astrazeneca, about: “Collaborative practices for medicinal chemistry research across the big pharma and not-for-profit interface”

David Andrews, Astrazeneca, about: “Collaborative practices for medicinal chemistry research across the big pharma and not-for-profit interface”

David Andrews is speaking about the main message of his publication ‘Collaborative practices for medicinal chemistry research across the big pharma and not-for-profit interface’ (see also the abstract below). He explains why collaboration between academia and industry is important and finally gives advices. Collaborative practices for medicinal chemistry research across the big pharma and not-for-... »

Azzurra Morreale, University of Palermo, about: “Open innovation: A real option to restore value to the biopharmaceutical R&D”

Azzurra Morreale, University of Palermo, about: “Open innovation: A real option to restore value to the biopharmaceutical R&D”

Azzurra Morreale is speaking about the main message of her publication ‘Open innovation: A real option to restore value to the biopharmaceutical R&D’ (see also the abstract below). She explains why collaboration between academia and industry is important and finally gives advices. Open innovation: A real option to restore value to the biopharmaceutical R&D by Giovanna Lo Nigro, Azzurra Mor... »

Elicia Maine, Beedie School of Business, about “The role of entrepreneurial decision-making in opportunity creation and recognition”

Elicia Maine, Beedie School of Business, about “The role of entrepreneurial decision-making in opportunity creation and recognition”

Elicia Maine is speaking about the main message of her publication ‘The role of entrepreneurial decision-making in opportunity creation and recognition’ (see also the abstract below). She explains why collaboration between academia and industry is important and finally gives advices.   The role of entrepreneurial decision-making in opportunity creation and recognition by Elicia Maine, Pek-Hoo... »

Stephen Roper, Enterprise Research Centre and Warwick Business School, about “Knowledge stocks, knowledge flows and innovation: Evidence from matched patents and innovation panel data”

Stephen Roper, Enterprise Research Centre and Warwick Business School, about “Knowledge stocks, knowledge flows and innovation: Evidence from matched patents and innovation panel data”

Stephen Roper, is speaking about the main message of his publication ‘Knowledge stocks, knowledge flows and innovation: Evidence from matched patents and innovation panel data’ (see also the abstract below). He explains why collaboration between academia and industry is important and finally gives advices. Knowledge stocks, knowledge flows and innovation: Evidence from matched patents and innovati... »

Page 1 of 212